Candel therapeutics appoints seshu tyagarajan, ph.d., rac, as chief technical and development officer

Needham, mass., march 02, 2022 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that seshu tyagarajan ph.d., rac, has been named as the company's chief technical and development officer.
CADL Ratings Summary
CADL Quant Ranking